Attaining OpEx is crucial for maintaining sustainability and competitiveness

The pharmaceutical industry in India is at a critical juncture, full of enormous promise and substantial responsibilities. The stakes are great and the world stage is prepared. A continual improvement approach, supported by investments in talent, technology, and teamwork, is essential for success. Companies that want to prosper in this changing environment must address operational excellence (OpEx) issues, change supply chains, and promote an innovative culture.

- 

India's pharmaceutical sector, valued at approximately $31 billion in 2023, holds immense promise, evolving rapidly to claim its place as a cornerstone of the global healthcare landscape. With a projected annual growth rate of 10-12 per cent, the industry aims to reach a market size of approx. $33 billion by 2025. India supplies 31 per cent of US pharmaceutical imports and boasts a 15 per cent growth rate in exports, solidifying its position as a leader in affordable medicine.

These figures emphasise both opportunities and challenges that demand a sharp focus on operational excellence (OpEx). Reflecting on the industry's growth trajectory, one cannot overlook its resilience in addressing domestic demand while expanding its global footprint. Yet, the journey is fraught with systemic challenges. Achieving OpEx is imperative to ensure sustainability and competitiveness in a rapidly evolving market.

The Dual Challenge: Growth and Sustainability

Cost management emerges as a critical priority. Rising expenses for raw materials, labour, and logistics put pressure on profitability. Adopting lean manufacturing principles, optimising asset utilisation, and minimising waste can significantly improve margins. Tailored frameworks help organisations address inefficiencies, enhance asset availability, and streamline operations, transforming cost management from a challenge into a driver of innovation and efficiency.